Sikander Ailawadhi

Jan 10, 2025 | ajmc.com | Sikander Ailawadhi

OpinionVideoJanuary 10, 2025Author(s):Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.

Aug 28, 2024 | nature.com | Saurabh Zanwar |Jonas Paludo |Ronald S. Go |Joselle M. Cook |Sikander Ailawadhi |Thomas M Habermann | +10 more

An under-recognized source of bleeding in Waldenström macroglobulinemia (WM) is the development of an acquired von Willebrand syndrome (AVWS) [1]. In WM, the von Willebrand Factor (vWF) glycoprotein can be degraded due to autoantibody destruction, increased shear stress due to hyperviscosity, or sequestered due to adsorption onto malignant cells, leading to the development of AVWS (AVWS-WM) [1, 2].

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.

Mar 7, 2024 | onclive.com | Sikander Ailawadhi

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses implications of early efficacy and safety findings foriopofosine I 131 (CLR 131) in heavily pretreated patients with various B-cell malignancies, including Waldenström macroglobulinemia.

Feb 29, 2024 | mdpi.com | Omar Nadeem |Sikander Ailawadhi |Jack Khouri |Louis Williams

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.